AFP and hepatocellular carcinoma: A suite of biomarkers with high diagnostic sensitivity and specificity can be used as for ancillary detection in current HCC-screening methods in primary care to ameliorate the current situation of a low HCC detection rate, particularly for AFP-negative patients with small nodules, whose diagnosis is challenging.